BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $884,539 | -26.0% | 12,989 | -11.3% | 0.00% | 0.0% |
| Q2 2023 | $1,195,621 | +20.7% | 14,648 | +9.7% | 0.00% | 0.0% |
| Q1 2023 | $990,810 | -52.2% | 13,356 | -46.3% | 0.00% | 0.0% |
| Q4 2022 | $2,071,342 | +347.4% | 24,881 | +1425.5% | 0.00% | +100.0% |
| Q3 2022 | $463,000 | -14.1% | 1,631 | -2.7% | 0.00% | -33.3% |
| Q2 2022 | $539,000 | -17.8% | 1,677 | +10.8% | 0.00% | 0.0% |
| Q1 2022 | $656,000 | -53.7% | 1,513 | -44.8% | 0.00% | -50.0% |
| Q4 2021 | $1,417,000 | +7.1% | 2,741 | +0.4% | 0.01% | 0.0% |
| Q3 2021 | $1,323,000 | +3.1% | 2,731 | -4.1% | 0.01% | 0.0% |
| Q2 2021 | $1,283,000 | +4.2% | 2,849 | -11.6% | 0.01% | +20.0% |
| Q1 2021 | $1,231,000 | +16.5% | 3,224 | -3.1% | 0.01% | 0.0% |
| Q4 2020 | $1,057,000 | +24.6% | 3,326 | -2.7% | 0.01% | +25.0% |
| Q3 2020 | $848,000 | +1.1% | 3,420 | +7.8% | 0.00% | 0.0% |
| Q2 2020 | $839,000 | +58.9% | 3,174 | +14.2% | 0.00% | +33.3% |
| Q1 2020 | $528,000 | +1.1% | 2,780 | +16.9% | 0.00% | +50.0% |
| Q4 2019 | $522,000 | +7.9% | 2,379 | -3.8% | 0.00% | 0.0% |
| Q3 2019 | $484,000 | -6.2% | 2,473 | +0.0% | 0.00% | -33.3% |
| Q2 2019 | $516,000 | +2.2% | 2,472 | -2.7% | 0.00% | 0.0% |
| Q1 2019 | $505,000 | +28.5% | 2,540 | -6.6% | 0.00% | +50.0% |
| Q4 2018 | $393,000 | -41.9% | 2,719 | -18.1% | 0.00% | -33.3% |
| Q3 2018 | $677,000 | +29.4% | 3,318 | -6.3% | 0.00% | 0.0% |
| Q2 2018 | $523,000 | -3.1% | 3,542 | -0.9% | 0.00% | 0.0% |
| Q1 2018 | $540,000 | +14.2% | 3,573 | -1.9% | 0.00% | +50.0% |
| Q4 2017 | $473,000 | +3.3% | 3,643 | -4.0% | 0.00% | 0.0% |
| Q3 2017 | $458,000 | +21.8% | 3,796 | +18.5% | 0.00% | 0.0% |
| Q2 2017 | $376,000 | +25.8% | 3,204 | +8.5% | 0.00% | 0.0% |
| Q1 2017 | $299,000 | -53.6% | 2,954 | -52.8% | 0.00% | -50.0% |
| Q4 2016 | $645,000 | -25.2% | 6,265 | -20.4% | 0.00% | -20.0% |
| Q3 2016 | $862,000 | +72.1% | 7,873 | +77.2% | 0.01% | +66.7% |
| Q2 2016 | $501,000 | -0.6% | 4,442 | -16.7% | 0.00% | 0.0% |
| Q1 2016 | $504,000 | -21.5% | 5,335 | -25.1% | 0.00% | -25.0% |
| Q4 2015 | $642,000 | -2.3% | 7,123 | +0.1% | 0.00% | 0.0% |
| Q3 2015 | $657,000 | +30.6% | 7,115 | +39.3% | 0.00% | +33.3% |
| Q2 2015 | $503,000 | -3.5% | 5,109 | -1.5% | 0.00% | 0.0% |
| Q1 2015 | $521,000 | -22.8% | 5,189 | -29.0% | 0.00% | -25.0% |
| Q4 2014 | $675,000 | – | 7,311 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |